Company intelligence / Profile preview

Molecular Biometrics

Chester, New Jersey, United Statesmolecularbiometrics.com ↗

Ownership: Private
Employees: ~8
Development stage: Other

Overview

Molecular Biometrics developed a non-invasive diagnostic test, ViaTest-E, to improve embryo selection in IVF using metabolomic profiling. The technology was validated in studies involving about 1,500 patients across the US, Europe, and Japan. The company also explored applications in neurodegenerative disease diagnostics but did not reach commercialization before becoming inactive. No recent clinical results are available beyond early-stage trials and regulatory discussions from around 2010.

Therapeutic areas: NeurologyWomen's Health
Modalities: Metabolomics-based diagnosticsBiospectroscopy platforms
Industry: Metabolite Diagnostics

Partnerships

Collaborations with academic investigators in the US, Europe, Japan; licensed patents from McGill University

Beyond the preview

Go deeper on Molecular Biometrics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Molecular Biometrics.

Explore the full profile